Lynn E Heasley

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1464026/publications.pdf

Version: 2024-02-01

48 papers	3,293 citations	257450 24 h-index	214800 47 g-index
50 all docs	50 docs citations	50 times ranked	5036 citing authors

#	Article	IF	Citations
1	Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2012, 18, 1472-1482.	7.0	1,018
2	Fibroblast Growth Factor (FGF) and FGF Receptor-Mediated Autocrine Signaling in Non-Small-Cell Lung Cancer Cells. Molecular Pharmacology, 2009, 75, 196-207.	2.3	211
3	Autocrine and paracrine signaling through neuropeptide receptors in human cancer. Oncogene, 2001, 20, 1563-1569.	5.9	192
4	Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration. Clinical Cancer Research, 2018, 24, 5368-5380.	7.0	189
5	FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies. Clinical Cancer Research, 2014, 20, 3299-3309.	7.0	141
6	Rapidly Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in NSCLC Cell Lines through De-Repression of FGFR2 and FGFR3 Expression. PLoS ONE, 2010, 5, e14117.	2.5	130
7	The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade. Cancer Immunology Research, 2017, 5, 767-777.	3.4	120
8	Fibroblast Growth Factor Receptors Are Components of Autocrine Signaling Networks in Head and Neck Squamous Cell Carcinoma Cells. Clinical Cancer Research, 2011, 17, 5016-5025.	7.0	91
9	Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma. OncoImmunology, 2017, 6, e1356153.	4.6	89
10	Cancer Cellâ€“Intrinsic Expression of MHC Class II Regulates the Immune Microenvironment and Response to Antiâ€“PD-1 Therapy in Lung Adenocarcinoma. Journal of Immunology, 2020, 204, 2295-2307.	0.8	83
11	FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers. Clinical Cancer Research, 2015, 21, 4356-4364.	7.0	75
12	Expression and role of the embryonic protein SOX2 in head and neck squamous cell carcinoma. Carcinogenesis, 2014, 35, 1636-1642.	2.8	66
13	Akt negatively regulates the cJun N-terminal kinase pathway in PC12 cells. Journal of Neuroscience Research, 2000, 62, 799-808.	2.9	65
14	EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases. Cancer Research, 2017, 77, 3551-3563.	0.9	65
15	The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer. Drug Resistance Updates, 2009, 12, 95-102.	14.4	56
16	JNK regulation of oncogenesis. Molecules and Cells, 2006, 21, 167-73.	2.6	55
17	Fibroblast growth factor receptor 1 amplification is a common event in squamous cell carcinoma of the head and neck. Modern Pathology, 2013, 26, 1298-1306.	5.5	54
18	Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC. Cancer Research, 2015, 75, 4398-4406.	0.9	53

#	Article	IF	Citations
19	Hypoxia Regulates Alternative Splicing of HIF and non-HIF Target Genes. Molecular Cancer Research, 2014, 12, 1233-1243.	3.4	46
20	A Receptor Tyrosine Kinase Network Composed of Fibroblast Growth Factor Receptors, Epidermal Growth Factor Receptor, v-erb-b2 Erythroblastic Leukemia Viral Oncogene Homolog 2, and Hepatocyte Growth Factor Receptor Drives Growth and Survival of Head and Neck Squamous Carcinoma Cell Lines. Molecular Pharmacology, 2013, 83, 882-893.	2.3	41
21	Nonamplified FGFR1 Is a Growth Driver in Malignant Pleural Mesothelioma. Molecular Cancer Research, 2014, 12, 1460-1469.	3.4	38
22	Persistence of Bronchial Dysplasia Is Associated with Development of Invasive Squamous Cell Carcinoma. Cancer Prevention Research, 2016, 9, 96-104.	1.5	34
23	Stress- and cell type-dependent regulation of transfected c-Jun N-terminal kinase and mitogen-activated protein kinase kinase isoforms. Biochemical Journal, 1999, 338, 681-686.	3.7	29
24	Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells. Lung Cancer, 2017, 109, 1-8.	2.0	27
25	Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities. Molecular Cancer, 2018, 17, 60.	19.2	27
26	Inhibition of EphB4â€“Ephrin-B2 Signaling Enhances Response to Cetuximabâ€“Radiation Therapy in Head and Neck Cancers. Clinical Cancer Research, 2018, 24, 4539-4550.	7.0	24
27	Altered Cell-Cycle Control, Inflammation, and Adhesion in High-Risk Persistent Bronchial Dysplasia. Cancer Research, 2018, 78, 4971-4983.	0.9	23
28	Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy. Bioinformatics, 2014, 30, 2393-2398.	4.1	22
29	A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer. Npj Precision Oncology, 2021, 5, 41.	5.4	22
30	Tyrosine kinase growth factor receptors but not seven-membraneâ€“spanning receptors or phorbol esters activate mitogen-activated protein kinase in rat hepatocytes. Hepatology, 1995, 22, 1296-1303.	7.3	19
31	Identifying kinase dependency in cancer cells by integrating high-throughput drug screening and kinase inhibition data. Bioinformatics, 2015, 31, 3799-3806.	4.1	17
32	Role of epidermal growth factor receptor inhibitor-induced interferon pathway signaling in the head and neck squamous cell carcinoma therapeutic response. Journal of Translational Medicine, 2021, 19, 43.	4.4	17
33	MERTK as a novel therapeutic target in head and neck cancer. Oncotarget, 2016, 7, 32678-32694.	1.8	17
34	Linking tyrosine kinase inhibitor-mediated inflammation with normal epithelial cell homeostasis and tumor therapeutic responses. , 2018, 1, 118-125.		13
35	Cancer Cell-Specific Major Histocompatibility Complex II Expression as a Determinant of the Immune Infiltrate Organization and Function in the NSCLC Tumor Microenvironment. Journal of Thoracic Oncology, 2021, 16, 1694-1704.	1.1	12
36	FGFR1 as a novel prognostic and predictive biomarker in squamous cell cancers of the lung and the head and neck area. Annals of Translational Medicine, 2013, 1, 23.	1.7	12

#	Article	IF	Citations
37	Preselection of Lung Cancer Cases Using FGFR1 mRNA and Gene Copy Number for Treatment With Ponatinib. Clinical Lung Cancer, 2019, 20, e39-e51.	2.6	11
38	Translating mesothelioma molecular genomics and dependencies into precision oncology-based therapies. Seminars in Cancer Biology, 2020, 61, 11-22.	9.6	11
39	Evaluation of FGFR3 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma. Targeted Oncology, 2016, 11, 631-642.	3.6	10
40	Therapeutic opportunity in innate immune response induction by oncogene-targeted drugs. Future Medicinal Chemistry, 2019, 11, 1083-1086.	2.3	10
41	Functional RNAi Screens Define Distinct Protein Kinase Vulnerabilities in EGFR-Dependent HNSCC Cell Lines. Molecular Pharmacology, 2019, 96, 862-870.	2.3	10
42	Role of EphB3 Receptor in Mediating Head and Neck Tumor Growth, Cell Migration, and Response to PI3K Inhibitor. Molecular Cancer Therapeutics, 2018, 17, 2049-2059.	4.1	9
43	Subcellular Localization and Activity of the Mitogen-Activated Protein Kinase Kinase 7 (MKK7)Î³Isoform are Regulated through Binding to the Phosphatase Calcineurin. Molecular Pharmacology, 2019, 95, 20-32.	2.3	6
44	TP53 Null Mutations Identify Lung Cancer Cell Lines with Highest Sensitivity to the Nontaxane Microtubule Inhibitor Eribulin. Molecular Pharmacology, 2021, 100, 144-154.	2.3	6
45	An Inducible TGF-Î²2-TGFÎ²R Pathway Modulates the Sensitivity of HNSCC Cells to Tyrosine Kinase Inhibitors Targeting Dominant Receptor Tyrosine Kinases. PLoS ONE, 2015, 10, e0123600.	2.5	5
46	A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines. Clinical Lung Cancer, 2018, 19, 450-456.	2.6	4
47	Analysis of Drug Resistance Using Kinome-Wide Functional Screens. Methods in Molecular Biology, 2017, 1636, 163-177.	0.9	2
48	Using CDKN2A loss in the context of wildtype TP53 to predict sensitivity for the MDM2 inhibitor milademetan.. Journal of Clinical Oncology, 2022, 40, 3136-3136.	1.6	0